Title

Single-shot TAP Block vs Continuous TAP Block
Randomized, Prospective, Double Blind Study Comparing Single Shot Versus Continuous Transverses Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Live Donor Nephrectomy
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Study Participants

    70
The purpose of this study is to determine whether continuous transversus abdominis plane (TAP) block is superior to single shot TAP for postoperative pain after laparoscopic donor nephrectomy
This study is a randomized, prospective, double blind study comparing single shot versus continuous transversus abdominis plane (TAP) block for postoperative analgesia after laparoscopic live donor nephrectomy.

Good pain control after surgery has been shown to decrease complications. To address the problem of postoperative pain control in donor nephrectomy patients,the study investigators began performing Transversus Abdominis Plane (TAP) blocks. The TAP block involves injection of local anesthetic between the abdominal muscle planes (internal oblique muscle and transversus abdominis muscle), to block the somatic nerves that supply sensation to the skin, muscles, and parietal peritoneum of the anterior abdominal wall. Prior reports of TAP blocks have shown that it provides good analgesia for postoperative pain after abdominal surgery. However because the duration of postoperative pain exceeds that of the single shot TAP block, the investigators hypothesized that by placing a catheter through which a continuous infusion of local anesthetic could be delivered, investigators could provide analgesia throughout the postoperative period. The study investigators also hypothesized that improved analgesia would decrease the need for opioid pain medications, hence decreasing the side effects associated with opioid use.

This study is designed to test our hypothesis that placing a TAP catheter is superior to single shot TAP, because it provides a longer duration of analgesia and decreases narcotic use.
Study Started
Jul 31
2012
Primary Completion
Dec 31
2015
Study Completion
Dec 31
2015
Results Posted
May 16
2017
Last Update
Aug 04
2020

Device TAP-C

TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.

  • Other names: Continuous TAP catheter

Drug TAP-S

Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.

  • Other names: Single shot TAP block

Placebo Group (TAP-S) Placebo Comparator

(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter

Active Group (TAP-C) Active Comparator

(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter

Criteria

Inclusion criteria:

Healthy subject undergoing laparoscopic live donor nephrectomy
(ASA) American Society of Anesthesiologists class 1 or 2
Age 18 or older, male or female
Desires TAP block for postoperative pain control

Exclusion criteria:

Any contraindication for TAP block - single or continuous
History of substance abuse
Any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.
Known allergy or other contraindications to the study medications (Ropivacaine, Normal Saline, Hydromorphone, Oxycodone and Acetaminophen)

Summary

Placebo Group (TAP-S)

Active Group (TAP-C)

All Events

Event Type Organ System Event Term

Total Narcotic Usage at 48 Hours

The primary endpoint of this study will be narcotic requirement at 48 hours

Placebo Group (TAP-S)

2.44
mg (Mean)
Standard Error: 0.43

Active Group (TAP-C)

2.88
mg (Mean)
Standard Error: 0.59

Secondary Endpoints Measured Will be Total Narcotic Usage at 60 Hours

All narcotic usage will be recorded at 1,12,24,36,48, and 60 hours. All narcotics will be converted to morphine equivalent for statistical calculation. These values reflect the total amount of narcotic used after combining all the data collected from each time point.

Placebo Group (TAP-S)

14.31
mg (Mean)
Standard Error: 2.12

Active Group (TAP-C)

14.4
mg (Mean)
Standard Error: 1.73

Average Pain Scores

Post- operative VAS pain scores (range of 0-10. 0 being no pain and 10 being worst pain) will be recorded at 1,12, 24, 36,48 and 60 hours. The values at each time points were combined and averaged.

Placebo Group (TAP-S)

5.31
units on a scale (Mean)
Standard Error: 0.34

Active Group (TAP-C)

5.06
units on a scale (Mean)
Standard Error: 0.31

Nausea Scores at 48 Hours

Post-operative nausea scores will be recorded at 48 hours. Range of nausea score is 0-3. 0= None, 1=Mild, 2=Moderate, 3=Severe.

Placebo Group (TAP-S)

0.34
units on a scale (Mean)
Standard Error: 0.12

Active Group (TAP-C)

0.34
units on a scale (Mean)
Standard Error: 0.11

Sedation Scores at 48 Hours

Post-operative sedation scores will be recorded at 48 hours. Range of score is 0-3. 0=Awake and Alert, 1=Quietly Awake, 2=Asleep and Arousable, 3=Deep sleep.

Placebo Group (TAP-S)

0.2
units on a scale (Mean)
Standard Error: 0.08

Active Group (TAP-C)

0.06
units on a scale (Mean)
Standard Error: 0.04

Total

70
Participants

Age, Continuous

41.09
years (Mean)
Standard Deviation: 11.16

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Placebo Group (TAP-S)

Active Group (TAP-C)